Literature DB >> 2723114

Influence of demographic factors on cyclosporine pharmacokinetics in adult uremic patients.

J Grevel1, K L Reynolds, L P Rutzky, B D Kahan.   

Abstract

The causes of variability in cyclosporine (CS) clearance (CL) are mostly unknown. The pharmacokinetics of CS were studied in 30 adult uremic patients after single intravenous and oral doses by analyzing serial concentrations in serum by radioimmunoassay (SR) and in whole blood by radioimmunoassay (WR) and high pressure liquid chromatography (WH). Bioavailability (F) and CL were calculated by noncompartmental models and were significantly different depending upon the assay method except for FSR = FWR: FSR = 43.2 +/- 21.7%; FWR = 43.5 +/- 18.5%; FWH = 36.4 +/- 17.3%; CLSR = 849 +/- 363 ml/min; CLWR = 380 +/- 156 ml/min; CLWH = 559 +/- 174 ml/min. The age of the patients and parameters describing body size such as weight, surface area and percent of ideal weight were not correlated with CL. The height of the patients correlated with CLWH but not CLSR or CLWR. Parameters responsible for CS binding in blood such as cholesterol, triglyceride, hemoglobin concentration or hematocrit did not explain variability in CL. Of the factors indicative of liver function alanine transaminase activity but not aspartate transaminase, lactate dehydrogenase, alkaline phosphatase activity nor total bilirubin concentration in serum was correlated with CL. F was not correlated with any of the demographic factors except for alanine transaminase. None of the significant correlations explained enough of the variability to afford a reliable prediction of CL or F.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723114     DOI: 10.1002/j.1552-4604.1989.tb03324.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Insights into the effects of hyperlipoproteinemia on cyclosporine A biodistribution and relationship to renal function.

Authors:  Hamidreza Montazeri Aliabadi; Tara J Spencer; Parvin Mahdipoor; Afsaneh Lavasanifar; Dion R Brocks
Journal:  AAPS J       Date:  2006-10-27       Impact factor: 4.009

Review 3.  Cyclosporin clinical pharmacokinetics.

Authors:  A Fahr
Journal:  Clin Pharmacokinet       Date:  1993-06       Impact factor: 6.447

4.  Dose adjustment strategy of cyclosporine A in renal transplant patients: evaluation of anthropometric parameters for dose adjustment and C0 vs. C2 monitoring in Japan, 2001-2010.

Authors:  Takatoshi Kokuhu; Keizo Fukushima; Hidetaka Ushigome; Norio Yoshimura; Nobuyuki Sugioka
Journal:  Int J Med Sci       Date:  2013-09-23       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.